Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when TVTX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsTravere raises $525M via convertible notes, using $351M to repurchase existing 2029 debt
Filed May 11, 2026 · Period ending May 6, 2026 · ~1 min read
Key Changes
-
high
Completed $525M offering of 0.50% convertible senior notes due 2032, convertible at $64.90/share (15.4 shares per $1,000 note). Conversion allowed when stock trades above $84.37 for 20 of 30 days, creating potential dilution if stock rises significantly.
Item 1.01 verify on EDGAR → -
high
Net proceeds of ~$508.5M will fund $350.9M repurchase of existing 2029 convertible notes ($221.4M principal plus accrued interest), with remainder for commercialization, R&D, and working capital. Debt refinancing extends maturity and reduces interest rate.
Item 8.01 verify on EDGAR → -
medium
Notes cannot be redeemed before May 2029; after that, only if stock exceeds $84.37 for 20 of 30 days and at least $75M notes remain outstanding. Limits company's flexibility to retire debt early unless stock performs well.
Item 1.01 verify on EDGAR → -
medium
Noteholders can force repurchase at par plus interest if fundamental change (acquisition, delisting) occurs, creating potential cash obligation that could impact M&A scenarios or require additional financing.
Item 1.01 verify on EDGAR → -
medium
Cross-default provision: default on other debt exceeding $50M triggers event of default on these notes if not cured within 60 days, creating interconnected risk across company's debt obligations.
Item 1.01 verify on EDGAR →
Summary
Travere Therapeutics completed a $525 million convertible debt offering on May 11, 2026, issuing notes with a 0.50% interest rate maturing in 2032. The notes convert to common stock at $64.90 per share, representing a premium to current trading levels. Underwritten by J.P. Morgan, Jefferies, and Leerink Partners, the offering included a $50 million over-allotment option that was fully exercised.
The company is using approximately $508.5 million two-thirds of the net proceeds ($351M) to repurchase its existing 2029 convertible notes, effectively refinancing higher-cost debt with lower-rate, longer-maturity obligations. The remaining proceeds will fund commercialization activities, research and development, and general corporate purposes.
This debt restructuring extends Travere's maturity profile and reduces near-term refinancing risk, though it creates potential future dilution if the stock price rises above conversion thresholds. Investors should monitor the stock's performance relative to the $84.37 threshold (130% of conversion price), as sustained trading above this level would trigger conversion rights and potential equity dilution. The cross-default provisions and fundamental change clauses also warrant attention in any future M&A scenarios or if the company faces financial stress on other obligations.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Item 1.01 — Entry into a Material Definitive Agreement filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
pursuant to the underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Jefferies LLC and Leerink Partners LLC, as representatives of the several underwriters (the “Underwriters”)
The offering was underwritten by major investment banks J.P. Morgan, Jefferies, and Leerink Partners. This indicates institutional support for the transaction and suggests the company successfully marketed the notes to investors through established financial intermediaries.
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
$50.0 million aggregate principal amount of Notes sold pursuant to the full exercise of the underwriters’ option to purchase additional Notes, solely to cover over-allotments.
The company completed a public offering of convertible senior notes totaling $350 million (including $50 million from the underwriters' over-allotment option). The notes carry a 0.50% annual interest rate and mature on May 15, 2032. This debt issuance provides the company with capital but creates future obligations and potential dilution if converted to equity.
Added in current filing · verify on EDGAR →
The initial conversion rate for the Notes is 15.4078 shares of the Company’s common stock per $1,000 principal amount of Notes, which represents an initial conversion price of approximately $64.90 per share.
Noteholders can convert their debt into common stock at a conversion price of approximately $64.90 per share, representing a premium to the stock price at issuance. Conversion is only allowed under specific conditions, including when the stock trades above 130% of the conversion price for at least 20 of 30 trading days in a quarter, or during the final months before maturity. This creates potential future dilution for existing shareholders if the stock price rises significantly.
Added in current filing · verify on EDGAR →
a default by the Company or any of the Company’s significant subsidiaries (as defined in the Indenture) with respect to any one or more mortgages, agreements, or other instruments under which there is outstanding, or by which there is secured or evidenced, any indebtedness for money borrowed with a principal amount of at least $50.0 million (or its foreign currency equivalent) in the aggregate
The indenture includes a cross-default provision where a default on other debt of $50 million or more (if not cured within 60 days) would trigger an event of default on these notes. This creates interconnected risk across the company's debt obligations and could accelerate repayment requirements if the company faces financial stress on other borrowings.
Event · Item 2.03 — Creation of a Direct Financial Obligation
Travere Therapeutics created a direct financial obligation or off-balance sheet arrangement, with details cross-referenced to Item 1.01.
Added in current filing · verify on EDGAR →
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in Item 1.01 is incorporated by reference into this Item 2.03.
The company disclosed the creation of a direct financial obligation or an off-balance sheet arrangement. The 8-K references Item 1.01 for full details, but Item 1.01 content is not provided in this filing excerpt. This typically indicates new debt, credit facility, lease obligation, or similar financial commitment.
Event · Item 3.02 — Unregistered Sales of Equity Securities
Travere priced $475M convertible notes offering; will use ~$351M to repurchase existing 2029 notes, remainder for general corporate purposes.
Added in current filing · verify on EDGAR →
On May 6, 2026, the Company entered into the Underwriting Agreement with the Underwriters, pursuant to which the Company agreed to sell $475.0 million aggregate principal amount of Notes and, at the option of the Underwriters, up to an additional $50.0 million aggregate principal amount of Notes, solely to cover over-allotments.
Travere entered into an underwriting agreement to sell $475 million in convertible notes, with an additional $50 million available for over-allotments. The notes convert at an initial rate of 22.3413 shares per $1,000 principal, potentially issuing up to 11,729,182 shares of common stock upon conversion.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
To the extent that any shares of Common Stock are issued upon conversion of the Notes (the “Conversion Shares”), and at the time of conversion there is not then an effective registration statement relating to the issuance of the Conversion Shares, they will be issued in transactions anticipated to be exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”), by virtue of Section 3(a) (9) thereof because no commission or other remuneration is expected to be paid in connection with any conversion of the Notes and any resulting issuance of shares of Common Stock.
If the notes convert to common stock without an effective registration statement in place, the shares will be issued under a Securities Act exemption (Section 3(a)(9)) because no commissions or remuneration will be paid for the conversion. This is a standard disclosure for convertible note offerings.
Event · Item 9.01 — Financial Statements and Exhibits
Item 9.01 — Financial Statements and Exhibits filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Supplemental Indenture, dated May 11, 2026, between the Company and U.S. Bank Trust Company, National Association, as Trustee (including the form of 0.50% Convertible Senior Note due 2032).
Travere completed an offering of 0.50% convertible senior notes maturing in 2032. The notes were issued under a base indenture and supplemental indenture with U.S. Bank Trust Company as trustee. This financing provides capital but creates future debt obligations and potential equity dilution upon conversion.
Added in current filing · verify on EDGAR →
Underwriting Agreement, dated May 6, 2026, by and among the Company, J.P. Morgan Securities LLC, Jefferies LLC and Leerink Partners LLC.
The convertible note offering was underwritten by J.P. Morgan Securities, Jefferies, and Leerink Partners under an agreement dated May 6, 2026. This indicates the offering was marketed and priced through investment banks, with associated underwriting fees reducing net proceeds.
Added in current filing · verify on EDGAR →
Launch Press Release of the Company dated May 5, 2026.
Travere publicly announced the convertible note offering on May 5, 2026, followed by pricing details on May 6, 2026. These press releases likely contain offering size, use of proceeds, and conversion terms that investors should review for full context.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 3, 2026 · How we verify